Iambic Therapeutics CFO converts 61,342 shares

The preferred stock converted automatically one-for-one immediately before completion of Iambic Therapeutics’ initial public offering.

Rhea-AI Filing Summary

Iambic Therapeutics, Inc. CFO & Chief Corp Dev Ofcr Michael Secora reported the conversion of 61,342 Series B-3 Convertible Preferred Stock shares into 61,342 common shares on October 16, 2026. Each preferred share automatically converted into one common share immediately before completion of the issuer’s initial public offering. Afterward, his reported direct holdings were 279,902 common shares, and his reported preferred-stock holdings were zero.

Insider Trade Summary

61,342 shares exercised/converted

Exercise 2 txns

Insider Secora Michael

Role CFO & Chief Corp Dev Ofcr

Type	Security	Shares	Price	Value
Conversion	Series B-3 Convertible Preferred Stock F1	61,342	$0.00	$0.00
Conversion	Common Stock F1	61,342	--	--

Holdings After Transaction: Series B-3 Convertible Preferred Stock — 0 contracts (Direct); Common Stock — 279,902 shares (Direct)

Footnotes (1)

1. F1. Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Key Figures

Series B-3 preferred shares converted: 61,342 shares Common shares acquired: 61,342 shares Common shares held directly after conversion: 279,902 shares +2 more

5 metrics

Series B-3 preferred shares converted 61,342 shares October 16, 2026

Common shares acquired 61,342 shares October 16, 2026

Common shares held directly after conversion 279,902 shares Reported following the October 16, 2026 transaction

Series B-3 preferred shares held after conversion 0 shares Reported following the October 16, 2026 transaction

Conversion ratio 1 common share per preferred share Automatic conversion immediately before completion of the initial public offering

Key Terms

Series B-3 Convertible Preferred Stock, one-to-one basis, initial public offering

3 terms

Series B-3 Convertible Preferred Stock financial

"Each share of Series B-3 Convertible Preferred Stock automatically converted"

one-to-one basis financial

"converted into Common Stock on a one-to-one basis"

initial public offering financial

"completion of the Issuer's initial public offering of Common Stock"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IAM shares did CFO Michael Secora acquire?

Michael Secora acquired 61,342 common shares through the conversion on October 16, 2026. His reported direct holdings after the transaction were 279,902 common shares.

How did IAM’s Series B-3 preferred stock convert?

Each share of Series B-3 Convertible Preferred Stock automatically converted into one common share immediately before completion of Iambic Therapeutics’ initial public offering. The preferred stock had no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 07:51 PM EDT Accepted by SEC EDGAR 10/19/2026 - 07:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Secora Michael

(Last) (First) (Middle)

C/O IAMBIC THERAPEUTICS, INC.

5627 OBERLIN DRIVE, SUITE 120

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Iambic Therapeutics, Inc. [ IAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Chief Corp Dev Ofcr

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2026		C		61,342	A	(1)	279,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B-3 Convertible Preferred Stock	(1)	10/16/2026		C			61,342	(1)	(1)	Common Stock	61,342	$0	0	D

Explanation of Responses:

1. Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

	/s/ Sunny Chang, by power of attorney	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)